New drug trial aims to tame rare blood and vessel diseases in kids

NCT ID NCT06512883

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a drug called benralizumab in children aged 6 to 18 with rare diseases where a type of white blood cell (eosinophils) causes inflammation and organ damage. The main goal is to see if the drug is safe and effective at controlling disease flares and reducing the need for steroid medications. Participants will receive injections every 4 weeks for at least one year, with an option to continue for another year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Aurora, Colorado, 80045, United States
Research Site
NOT_YET_RECRUITING

Cincinnati, Ohio, 45229, United States
Research Site
NOT_YET_RECRUITING

Highland Hills, Ohio, 44106-2624, United States
Research Site
RECRUITING

São Paulo, 01232-010, Brazil
Research Site
RECRUITING

Toronto, Ontario, M5G1X8, Canada
Research Site
NOT_YET_RECRUITING

Lille, 59037, France
Research Site
NOT_YET_RECRUITING

Montpellier, 34295, France
Research Site
NOT_YET_RECRUITING

Ahmedabad, 380013, India
Research Site
RECRUITING

Guadalajara, 44620, Mexico
Research Site
NOT_YET_RECRUITING

Rotterdam, 3015 GD, Netherlands
Research Site
NOT_YET_RECRUITING

Kielce, 25-734, Poland
Research Site
RECRUITING

Altındağ, 06230, Turkey (Türkiye)
Research Site
RECRUITING

Istanbul, 34093, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) HYPEREOSINOPHILIA SYNDROME (HES)